Frequency of hepatitis B virus-DNA among hepatitis B surface-Ag negative, anti-hepatitis B core antibody-positive blood donors in Yazd, Iran

Mahtab Vaziri, Hayedeh Javadzadeh Shahshahani

Abstract:
BACKGROUND: The diagnosis of hepatitis B infection in most blood transfusion centers is based on hepatitis B surface (HBs) antigen detection by an enzyme immunoassay method. This study aimed to determine the frequency of hepatitis B core (HBe) antibody, HBs antibody, and hepatitis B virus (HBV) DNA among HBs antigen-negative healthy blood donors of Yazd province, Iran.

MATERIALS AND METHODS: This cross-sectional study was conducted on 1500 healthy blood donor samples negative for HBs antigen, hepatitis C virus antibody, human immunodeficiency virus antibody/antibody, and rapid plasma regain tests. All samples were screened for HBe antibody test. HBs antibody and real-time polymerase chain reaction were performed for HBe antibody-positive samples.

RESULTS: HBc antibody was positive in 74 (4.9%) samples and 11 (14.9%) of 74 positive samples for HBc antibody were negative for HBs antibody. Sixty-three (85.1%) positive samples for HBc antibody had HBs antibody titer over 10 IU/L, and 43 (58.1%) had HBs antibody titer over 100 IU/L. There was no hepatitis B DNA-positive sample in the present study.

CONCLUSIONS: The study results suggest that there is a very low risk for transmission of HBV through blood donors of Yazd, Iran.

Keywords: Anti-hepatitis B core antibody, anti-hepatitis B surface antibody, blood donor, hepatitis B virus-DNA

Introduction

One of the most important concerns of blood transfusion centers worldwide is the transmission of hepatitis B infection through blood components. In Iran, blood transfusion centers, all of the donated blood is tested with seroprevalence hepatitis B surface (HBs)-Ag test by ELISA method. Blood units with reactive results are discarded and the confirmatory test is done if they are repeatedly reactive. Although this serologic method reduces the chance of hepatitis B transmission, studies have shown that HBsAg-negative blood components could lead to hepatitis B infection. Hepatitis B virus (HBV) infection may lead to acute, chronic, or sometimes occult hepatitis. Occult hepatitis B is defined as the presence of HBV-DNA in blood or liver without detectable HBsAg with or without hepatitis B core (anti-HBc) antibody.

Occult HBV infection may represent (i) acute infection in the window period, (ii) HBV tail-end of chronic HBV infection, (iii) persistence of replication at low level after recovery in the presence of anti-HBs antibody, or (iv) occurrence of an escape mutant in vaccinated or

How to cite this article: Vaziri M, Shahshahani HJ. Frequency of hepatitis B virus-DNA among hepatitis B surface-Ag negative, anti-hepatitis B core antibody-positive blood donors in Yazd, Iran. Asian J Transfus Sci 2021;15:179-82.
According to previous studies, the prevalence of occult hepatitis varies in different provinces of Iran. The prevalence rate in India, Pakistan, and Turkey is 0.15%, 3%, and 0%, respectively. Since there are no available data about the frequency of anti-HBc antibody and HBV-DNA in blood donors of Yazd, the present study aimed to investigate the frequency of HBV-DNA among anti-HBc antibody-positive blood donors of Yazd province.

Materials and Methods

In this cross-sectional study, 1500 healthy blood donor’s samples negative for HBsAg, hepatitis C virus (HCV)-Ab, HIV-Ag/Ab, and rapid plasma reagin were enrolled from 24 June to 13 May 2015. All of the blood samples were examined for anti-HBc antibody testing. Anti-HBc antibody-positive samples were tested for anti-HBs antibody and real-time polymerase chain reaction (PCR). Blood donor information was extracted from the blood transfusion software database and analysis was performed using SPSS software (IBM Corporation, New York, NY, USA).

Regular blood donor is defined as one who has donated at least two times in the past 12 months and lapsed donor is one who has donated blood >1 year ago. HBsAg, HCV-Ab, and HIV-Ag/Ab performed automatically by ELISA method ([Murex, Dartford, UK) and (Adaltis, Milan, Italia), respectively] and anti-HBc antibody and anti-HBs antibody performed manually ([Murex, Dartford, UK] and [Siemens, Germany], respectively). DNA was extracted from anti-HBc antibody-positive serums by high pure viral nucleic acid kit (Roche, Germany). Real-time PCR was done by the TaqMan probe with a quantitative molecular diagnostic kit (Altona, Hamburg, Germany). The kit had four standard samples that have 10⁴, 10³, 10², and 10 units of virus DNA in each microliter. The four standard samples and one negative control sample were used in each PCR reaction. Standard samples and negative control samples were used for the determination of virus quantity and measure of background fluorescent, respectively. The sensitivity of this kit was 0.5 IU/mL. Real-time PCR equipment was rotor gene 6000 of German Corbett Company. The present research project was approved by the Ethical Committee of High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

Results

Of the total, 96.7% were men. About 61.6% regular donors, 26% lapsed donors, and 12.4% were first-time donors. Anti-HBc antibody was positive in 74 donors (4.9%), of which 71 (96%) were male (4.9% of all male participants) and 3 (4%) were female (6% of all female participants). The frequency and characteristics of donors with anti-HBc antibody are shown in Table 1.

Of the 74 blood donors positive for anti-HBc antibody, 43 donors (58.1%) had anti-HBs antibody titer over 100 IU/L, 20 donors (27%) had anti-HBs antibody titer over 10 IU/L and <100 IU/L, and 11 donors (14.9%) had anti-HBs antibody titer under 10 IU/L [Table 2]. HBV-PCR was not positive in any of the samples.

Discussion

Knowledge about the frequency of HBV infection among blood donors is of paramount importance for implementing strategies to reduce transfusion-transmissible infections and increase blood safety.

In the present study, there was no significant difference in sexuality, marital, and donation status between blood donors with or without anti-HBc antibody. Relative seroprevalence of anti-HBc antibody positivity had an inverse relation with education that was not significant after the deletion of the age effect. There was a direct relation between relative seroprevalence of anti-HBc antibody and age (P = <0.001) [Table 1]. This could mean that probably older individuals lived longer with HBV that could provide the chance of viral mutation or adaptation with the host immune system and stable living with it. Various studies show that Hepatitis B prevalence is on the decrease in society.

Table 1: Characteristics of anti-hepatitis B core antibody positive blood donors in comparison with total study subjects

|                | Male (%) | Female (%) | Married (%) | Single (%) | 18-24 years (%) | 25-34 years (%) | 35-44 years (%) | ≥55 years (%) | Regular donor (%) | Lapsed donor (%) | First time donor (%) |
|----------------|----------|------------|-------------|------------|-----------------|-----------------|-----------------|---------------|-------------------|---------------------|---------------------|
| Anti-HBc antibody | 4.9      | 6          | 5.3         | 2.7        | 2               | 5.8             | 7.9             | 11            | 4.8               | 6.2                 | 3.2                 |
| Total           | 97       | 3          | 85          | 15         | 7               | 36              | 30              | 20            | 7                 | 62                  | 26                  |
There was no HBV-DNA positive sample in this study. There have been no reports of HBV transmission from blood components in recent studies in Iran. Different prevalence rates of occult hepatitis have been reported in different studies. It seems that virus endemicity and virus detection processes play important roles in these different results. Allain found that most of the blood donors with occult hepatitis B were over 45-year-old. In Iran, studies in different areas showed various prevalence rates of anti-HBc antibody and HBV-DNA in healthy HBsAg-negative donors [Table 3]. These differences could be due to different infection prevalence rates in each area. An Egyptian study in 2013 on 3167 HBsAg-negative blood donors showed that 14.2% had anti-HBc antibody and 17.2% of them were HBV-DNA positive. In that study, age over 30 years and being married were the most important risk factors for the prediction of anti-HBc antibody positivity and age under 30 years was a significant risk factor for HBV-DNA positivity prediction.

Viral transmission can be associated with extremely low levels of HBV-DNA in only anti-HBc antibody-positive units or blood collected during the early phase of acute infection, in which neither HBsAg nor HBV-DNA is detectable. In the present study, about 60% of anti-HBc antibody-positive blood donors had anti-HBs antibody titer higher than 100 IU/L and 85% had anti-HBs antibody titer higher than 10 IU/mL. There was no significant difference between different sexes, age, marital, educational, and donation status in anti-HBs antibody titer [Table 2]. Studies showed that high titer of anti-HBs antibody had protective effect against viral infection. Countries such as Germany, Austria, and Japan allow transfusion of units with anti-HBs antibody titer higher than 100 IU/L. Satake et al., in Japan, stated that there was no document of HBV infection in blood donors that had anti-HBc antibody and anti-HBs antibody together. Karimi et al. research results were also similar to the present study results; The seroprevalence rate of anti-HBc antibody was 4.9% and NAT test detects no HBV DNA.

**Conclusions**

The frequency of anti-HBc antibody positivity in Yazd blood donors was not high, and most of them had anti-HBs antibody titer over 100 IU/L that suggests it is not infective. There was no positive HBV-DNA sample in the study. Therefore, Yazd blood donors are low risk for transmission of hepatitis B infection.

**Acknowledgments**

The authors would like to thank Dr. Z. Sharifi, Dr. S.M. Hosseini and the staff of the Yazd blood transfusion center for their help in running the study.

**Financial support and sponsorship**

This study was financially supported by the High Institute for Research and Education in Transfusion Medicine.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Reesink HW, Engelf CP, Henn G, Mayr WR, Delage G, Bernier F, et al. Occult hepatitis B infection in blood donors. Vox Sang 2008;94:153-66.
2. Hollinger FB, Habibollahi P, Daneshmand A, Alavian SM. Occult hepatitis B infection in chronic hemodialysis patients: current concepts and strategy. Hepat Monday 2010;10:199-204.
3. Dufour DR. Hepatitis B surface antigen (HBsAg) assays – Are they good enough for their current uses? Clin Chem 2006;52:1457-9.
4. Delavari M, Shahabinejad N, Renzaho A, Zahedi M, Owhadi AR. Frequency of anti-HBc and HBV DNA detection in blood donors of Kerman province, Iran. J Blood Disord Transfus 2011;2:1-4.
5. Sofian M, Aghakhani A, Izadi N, Banifazl M, Kalantar E, Eslamifar A, et al. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. Int J Infect Dis 2010;14:e308-10.
6. Jafarzadeh A, Arababadi MK, Pourazar MM. Occult hepatitis B virus infection among blood donors with antibodies to hepatitis B core antigen. Acta Med Iran 2008;46:27-32.
7. Pourazar A, Salehi M, Jafarzadeh A, Arababadi MK, Oreizi F, Shariatinezhad K. Detection of HBV DNA in HBsAg negative normal blood donors. IJJ 2005;2:172-6.
8. Behzad-Behbahani A, Mafi-Nejad A, Tabei SZ, Lankarani KB, Torab A, Moaddeh A. Anti-HBc and HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J Med Res
9. Vaezjalali M, Rashidpour S, Rezaee H, Hajibeigi B, Zeidi M, Gachkar L, et al. Hepatitis B viral DNA among HBs antigen healthy blood donors. Hepat Mon 2013;13:e6590.

10. Makroo RN, Chowdhry M, Bhatia A, Arora B, Rosamma NL. Hepatitis B core antibody testing in Indian blood donors: A double-edged sword! Asian J Transfus Sci 2012;6:10-3.

11. Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: Implications for transfusion practice. Transfusion 2007;47:74-9.

12. Arabaci F, Oldacay M. Investigation of mutant hepatitis B virus in core antibody seropositive cases of blood donor population. J Med Sci 2008;8:316-20.

13. Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol 2011;17:1927-38.

14. Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M, Alavian SM. Hepatitis B virus infection in the general population of Iran: An updated systematic review and meta-analysis. Hepat Mon 2016;16:e35577.

15. Alavian SM, Miri SM, Hollinger FB, Jazayeri SM. Occult Hepatitis B (OBH) in clinical settings. Hepat Mon 2012;12:e6126.

16. Alavian SM, Hajarianzadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B virus infection in Iran: A systematic review. Hepat Mon 2008;8:28-94.

17. Kafiabad SA, Shahshahani JH, Vaziri M. A case of hepatitis B infection; is it transmitted via blood components? Arch Clin Infect Dis 2015;10:24434.

18. Amini S, Talebian A, Pourfath EA. Tracing blood units from recipients to their donors: Results of a trace back study for hepatitis B. Blood 2004;5:67-72.

19. Khamesipour A, Amiri ZM, Kafiabad SA, Saadat F, Mansour-ghanaei F, Esteghamati AR, et al. Frequency of hepatitis B virus DNA in anti-HBc positive, HBsAg negative blood donors in Rasht, northern Iran. Transfus Apher Sci 2011;45:195-7.

20. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009;51:798-809.

21. Ayatollahi J, Jahanbadi S, Shariyatjazi M, Hemayati R, Vakili M, Shahcheraghhi SH. The prevalence of occult hepatitis B virus in the hemodialysis patients in Yazd, Iran. Acta Med Iran 2016;54:784-7.

22. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001;41:878-84.

23. Soldan K, Barbara JA, Dow BC. Transfusion-transmitted hepatitis B virus infection in the UK: A small and moving target. Vox Sang 2002;83:305-8.

24. Katsoulidou A, Paraskevis D, Magiorkinis E, Moschidis Z, Haida C, Hatzitheodorou E, et al. Molecular characterization of occult hepatitis B cases in Greek blood donors. J Med Virol 2009;81:815-29.

25. Calderón GM, González-Velázquez F, González-Bonilla CR, Novelo-Garza B, Terrazas JJ, Martínez-Rodríguez ML, et al. Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico. Transfusion 2009;49:2200-7.

26. Minuk GY, Sun DF, Huang J, Zhang M, Caouette S, Nicolle LE, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005;42:480-5.

27. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007;47:1197-205.

28. Karimi G, Zadsar M, Vafaei N, Sharifi Z, Falahi-Tafti M. Prevalence of antibody to hepatitis B core antigen and Hepatitis B virus DNA in HBsAg negative healthy blood donors. Virol J 2016;13:36.